Modifying radiation damage

Current Drug Targets

Volumn 11, Issue 11, 2010, Pages 1352-1365

  Kim, Kwanghee ^a   McBride, William H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cytokines; Inflammation; NF B; RDS; TBI

Indexed keywords

ANTIOXIDANT; ATM PROTEIN; CIPROFLOXACIN; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; LYMPHOTOXIN; MANGANESE SUPEROXIDE DISMUTASE; METALLOTHIONEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TETRACYCLINE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CHROMATIN STRUCTURE; DNA DAMAGE; DNA REPAIR; FIBROSIS; HEALING; INNATE IMMUNITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; RADIATION INJURY; RADIATION PROTECTION; TISSUE INJURY; TRAUMATIC BRAIN INJURY; WHOLE BODY RADIATION; ANIMAL; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; PATHOLOGY; RADIATION EXPOSURE; REVIEW; WOUND HEALING;

ANIMALS; HUMANS; IMMUNE SYSTEM; RADIATION INJURIES; WOUND HEALING;

EID: 79955031549     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111009011352     Document Type: Article

References (225)

1. Seed TM. Radiation protectants: current status and future prospects. Health Phys 2005; 89(5): 531-45.
2. Murray D, McBride WH. Radioprotective agents. In: Kirk-Othmer Encyclopedia of Chemical Technology and Encyclopedia of Environmental Analysis and Remediation, I Kroschwitz and M Howe-Grant, Eds. John Wiley & Sons, New York, 1996: 963-1006.
3. Brizel DM. Pharmacologic approaches to radiation protection. J Clin Oncol 2007; 25(26): 4084-9.
4. Ainsworth EJ. Bacterial endotoxins and the radiation syndrome. Annu Rep Div Biol Med Res Argonne Natl Lab 1960; ANL-6264: 158-61.
5. Neta R, Oppenheim JJ. Radioprotection with cytokines--learning from nature to cope with radiation damage. Cancer Cells 1991; 3(10): 391-6.
6. Neta R, Oppenheim JJ, Douches, S. Interdependence of the radioprotective effects of human recombinant interleukin 1b, tumor necrosis factora, granulocyte colony stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor. J Immunol 1988; 140: 108-11.
7. Weiss W. Towards a coherent conceptual framework for emergency preparedness/response and rehabilitation-the application of the new ICRP recommendations given in ICRP 103. J Environ Radioact 2009; 100(12): 1002-4.
8. Singh VK, Shafran RL, Inal CE, Jackson WE, 3rd, Whitnall MH. Effects of whole-body gamma irradiation and 5-androstenediol administration on serum G-CSF. Immunopharmacol Immunotoxicol 2005; 27(4): 521-34.
9. McBride WH, Dougherty GJ. Radiotherapy for genes that cause cancer. Nat Med 1995; 1(11): 1215-7.
10. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11(1): 21-8.
11. McBride WH, Chiang CS, Olson JL, et al. A sense of danger from radiation. Radiat Res 2004; 162(1): 1-19.
12. Chapman JD, Stobbe CC, Gales T, et al. Condensed chromatin and cell inactivation by single-hit kinetics. Radiat Res 1999; 151(4): 433-41.
13. Biade S, Stobbe CC, Boyd JT, Chapman JD. Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int J Radiat Biol 2001; 77(10): 1033-42.
14. Falk M, Lukasova E, Kozubek S. Chromatin structure influences the sensitivity of DNA to gamma-radiation. Biochim Biophys Acta 2008; 1783(12): 2398-414.
15. Ikura T, Ogryzko VV, Grigoriev M, et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000; 102(4): 463-73.
16. Squatrito M, Gorrini C, Amati B. Tip60 in DNA damage response and growth control: many tricks in one HAT. Trends Cell Biol2006; 16(9): 433-42.
17. Carrozza MJ, Utley RT, Workman JL, Cote J. The diverse functions of histone acetyltransferase complexes. Trends Genet 2003; 19(6): 321-9.
18. Bird AW, Yu DY, Pray-Grant MG, et al. Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair. Nature 2002; 419(6905): 411-5.
19. Sun Y, Jiang X, Xu Y, et al. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol 2009; 11(11): 1376-82.
20. Murr R, Loizou JI, Yang YG, et al. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat Cell Biol 2006; 8(1): 91-9.
21. Kusch T, Florens L, Macdonald WH, et al. Acetylation by Tip60 is required for selective histone variant exchange at DNA lesions. Science 2004; 306(5704): 2084-7.
22. Sun Y, Chin YE, Weisiger E, et al. Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009; 182(10): 5899-903.
23. Xiao H, Chung J, Kao HY, Yang YC. Tip60 is a co-repressor for STAT3. J Biol Chem 2003; 278(13): 11197-204.
24. Loontiens FG, Regenfuss P, Zechel A, Dumortier L, Clegg RM. Binding characteristics of Hoechst 33258 with calf thymus DNA, poly[d(A-T)], and d(CCGGAATTCCGG): multiple stoichiometries and determination of tight binding with a wide spectrum of site affinities. Biochemistry 1990; 29(38): 9029-39.
25. Martin RF, Anderson RF. Pulse radiolysis studies indicate that electron transfer is involved in radioprotection by Hoechst 33342 and methylproamine. Int J Radiat Oncol Biol Phys 1998; 42(4): 827-31.
26. Denison L, Haigh A, D'Cunha G, Martin RF. DNA ligands as radioprotectors: molecular studies with Hoechst 33342 and Hoechst 33258. Int J Radiat Biol 1992; 61(4): 561.
27. Lyubimova NV, Coultas PG, Yuen K, Martin RF. In vivo radioprotection of mouse brain endothelial cells by Hoechst 33342. Br J Radiol 2001; 74(877): 77-82.
28. Singh SP, Jayanth VR, Chandna S, et al. Radioprotective effects of DNA ligands Hoechst-33342 and 33258 in whole body irradiated mice. Indian J Exp Biol 1998; 36(4): 375-84.
29. Tawar U, Bansal S, Shrimal S, Singh M, Tandon V. Nuclear condensation and free radical scavenging: a dual mechanism of bisbenzimidazoles to modulate radiation damage to DNA. Mol Cell Biochem 2007; 305(1-2): 221-33.
30. Newton GL, Ly A, Tran NQ, Ward JF, Milligan JR. Radioprotection of plasmid DNA by oligolysines. Int J Radiat Biol 2004; 80(9): 643-51.
31. Chiu S, Oleinick NL. Radioprotection against the formation of DNA double-strand breaks in cellular DNA but not native cellular chromatin by the polyamine spermine. Radiat Res 1997; 148(2): 188-92.
32. Chiu S, Oleinick NL. Radioprotection of cellular chromatin by the polyamines spermine and putrescine: preferential action against formation of DNA-protein crosslinks. Radiat Res 1998; 149(6): 543-9.
33. Kumar IP, Namita S, Goel HC. Modulation of chromatin organization by RH-3, a preparation of Hippophae rhamnoides, a possible role in radioprotection. Mol Cell Biochem 2002; 238(1-2): 1-9.
34. Goel HC, Prasad J, Singh S, Sagar RK, Kumar IP, Sinha AK. Radioprotection by a herbal preparation of Hippophae rhamnoides, RH-3, against whole body lethal irradiation in mice. Phytomedicine 2002; 9(1): 15-25.
35. Goel HC, Kumar IP, Samanta N, Rana SV. Induction of DNAprotein cross-links by Hippophae rhamnoides: implications in radioprotection and cytotoxicity. Mol Cell Biochem 2003; 245(1-2): 57-67.
36. Goel HC, Prasad J, Singh S, et al. Radioprotective potential of an herbal extract of Tinospora cordifolia. J Radiat Res (Tokyo) 2004; 45(1): 61-8.
37. Kim K, Pollard JM, Norris AJ, et al. High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin Cancer Res 2009; 15(23): 7238-45.
38. Kastan MB. DNA damage responses: mechanisms and roles in human disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol Cancer Res 2008; 6(4): 517-24.
39. Li Y, DeFatta R, Anthony C, Sunavala G, De Benedetti A. A translationally regulated Tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 2001; 20(6): 726-38.
40. Sen SP, De Benedetti A. TLK1B promotes repair of UV-damaged DNA through chromatin remodeling by Asf1. BMC Mol Biol 2006; 7: 37.
41. Sunavala-Dossabhoy G, De Benedetti A. Tousled homolog, TLK1, binds and phosphorylates Rad9; TLK1 acts as a molecular chaperone in DNA repair. DNA Repair (Amst) 2009; 8(1): 87-102.
42. Brown SL, Kolozsvary A, Liu J, Ryu S, Kim JH. Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. Radiat Res 2008; 169(4): 474-8.
43. Bae YS, Kang SW, Seo MS, et al. Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptormediated tyrosine phosphorylation. J Biol Chem 1997; 272(1): 217-21.
44. Joo CK, Kim HS, Park JY, Seomun Y, Son MJ, Kim JT. Ligand release-independent transactivation of epidermal growth factor receptor by transforming growth factor-beta involves multiple signaling pathways. Oncogene 2008; 27(5): 614-28.
45. Sarsour E, Kumar MG, Chaudhuri L, Kalen AL, Goswami P. Redox Control of the Cell Cycle in Health and Disease. Antioxid Redox Signal 2009; 11(12): 2985-3011.
46. Rithidech KN, Tungjai M, Arbab E, Simon SR. Activation of NFkappaB in bone marrow cells of BALB/cJ mice following exposure in vivo to low doses of (137)Cs gamma-rays. Radiat Environ Biophys 2005; 44(2): 139-43.
47. Linard C, Ropenga A, Vozenin-Brotons MC, Chapel A, Mathe D. Abdominal irradiation increases inflammatory cytokine expression and activates NF-kappaB in rat ileal muscularis layer. Am J Physiol Gastrointest Liver Physiol 2003; 285(3): G556-65.
48. Wang Y, Meng A, Lang H, et al. Activation of nuclear factor kappaB In vivo selectively protects the murine small intestine against ionizing radiation-induced damage. Cancer Res 2004; 64(17): 6240-6.
49. Egan LJ, Eckmann L, Greten FR, et al. IkappaB-kinasebetadependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 2004; 101(8): 2452-7.
50. Chen YJ, Liao HF, Tsai TH, Wang SY, Shiao MS. Caffeic acid phenethyl ester preferentially sensitizes CT26 colorectal adenocarcinoma to ionizing radiation without affecting bone marrow radioresponse. Int J Radiat Oncol Biol Phys 2005; 63(4): 1252-61.
51. Murley JS, Kataoka Y, Cao D, Li JJ, Oberley LW, Grdina DJ. Delayed radioprotection by NFkappaB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs. Radiat Res 2004; 162(5): 536-46.
52. Murley JS, Kataoka Y, Hallahan DE, Roberts JC, Grdina DJ. Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells. Free Radic Biol Med 2001; 30(12): 1426-39.
53. Eastgate J, Moreb J, Nick HS, Suzuki K, Taniguchi N, Zucali JR. A role for manganese superoxide dismutase in radioprotection of hematopoietic stem cells by interleukin-1. Blood 1993; 81(3): 639-46.
54. Wong GHW, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 1988; 242: 941-4.
55. Janssen YM, Van Houten B, Borm PJ, Mossman BT. Cell and tissue responses to oxidative damage. Lab Invest 1993; 69(3): 261-74.
56. Wong GH. Protective roles of cytokines against radiation: induction of mitochondrial MnSOD. Biochim Biophys Acta 1995; 1271(1): 205-9.
57. Murley JS, Kataoka Y, Baker KL, Diamond AM, Morgan WF, Grdina DJ. Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha. Radiat Res 2007; 167(4): 465-74.
58. Grdina DJ, Murley JS, Kataoka Y, et al. Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response. Int J Radiat Oncol Biol Phys 2009; 73(3): 886-96.
59. Nagata K, Iwasaki Y, Yamada T, et al. Overexpression of manganese superoxide dismutase by N-acetylcysteine in hyperoxic lung injury. Respir Med 2007; 101(4): 800-7.
60. Yi MJ, Park SH, Cho HN, et al. Heat-shock protein 25 (Hspb1) regulates manganese superoxide dismutase through activation of Nfkb (NF-kappaB). Radiat Res 2002; 158(5): 641-9.
61. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000; 6(8): 324-9.
62. Carpenter M, Epperly MW, Agarwal A, et al. Inhalation delivery of manganese superoxide dismutase-plasmid/liposomes protects the murine lung from irradiation damage. Gene Ther 2005; 12(8): 685-93.
63. Epperly MW, Defilippi S, Sikora C, Gretton J, Greenberger JS. Radioprotection of lung and esophagus by overexpression of the human manganese superoxide dismutase transgene. Mil Med 2002; 167(2 Suppl): 71-3.
64. Epperly MW, Guo HL, Jefferson M, et al. Cell phenotype specific kinetics of expression of intratracheally injected manganese superoxide dismutase-plasmid/liposomes (MnSOD-PL) during lung radioprotective gene therapy. Gene Ther 2003; 10(2): 163-71.
65. Yan S, Brown SL, Kolozsvary A, Freytag SO, Lu M, Kim JH. Mitigation of radiation-induced skin injury by AAV2-mediated MnSOD gene therapy. J Gene Med 2008; 10(9): 1012-8.
66. Zhang M, Qian J, Xing X, et al. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res 2008; 14(6): 1868-76.
67. Huang LE, Willmore WG, Gu J, Goldberg MA, Bunn HF. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 1999; 274(13): 9038-44.
68. Fishman K, Baure J, Zou Y, et al. Radiation-induced reductions in neurogenesis are ameliorated in mice deficient in CuZnSOD or MnSOD. Free Radic Biol Med 2009; 47(10): 1459-67.
69. Urano M, Kuroda M, Reynolds R, Oberley TD, St. Clair DK. Expression of manganese superoxide dismutase reduces tumor control radiation dose: gene-radiotherapy. Cancer Res 1995; 55(12): 2490-3.
70. Sun W, Kalen AL, Smith BJ, Cullen JJ, Oberley LW. Enhancing the antitumor activity of adriamycin and ionizing radiation. Cancer Res 2009; 69(10): 4294-300.
71. Thongphasuk J, Oberley LW, Oberley TD. Induction of superoxide dismutase and cytotoxicity by manganese in human breast cancer cells. Arch Biochem Biophys 1999; 365(2): 317-27.
72. Greenberger JS, Epperly MW. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. In vivo 2007; 21(2): 141-6.
73. Mitchell JA, Sheng H, Forstermann U, Murad F. Characterization of nitric oxide synthases in non-adrenergic non-cholinergic nerve containing tissue from the rat anococcygeus muscle. Br J Pharmacol 1991; 104(2): 289-91.
74. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN, et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med 2002; 33(6): 857-63.
75. Gauter-Fleckenstein B, Fleckenstein K, Owzar K, Jiang C, Batinic-Haberle I, Vujaskovic Z. Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med 2008; 44(6): 982-9.
76. Pollard JM, Reboucas JS, Durazo A, et al. Radioprotective effects of manganese-containing superoxide dismutase mimics on ataxiatelangiectasia cells. Free Radic Biol Med 2009; 47(3): 250-60.
77. Srinivasan V, Doctrow S, Singh VK, Whitnall MH. Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol 2008; 30(2): 271-90.
78. Haton C, Francois A, Vandamme M, Wysocki J, Griffiths NM, Benderitter M. Imbalance of the antioxidant network of mouse small intestinal mucosa after radiation exposure. Radiat Res 2007; 167(4): 445-53.
79. Pardo M, Tirosh O. Protective signalling effect of manganese superoxide dismutase in hypoxia-reoxygenation of hepatocytes. Free Radic Res 2009; 43(12): 1225-39.
80. Sekhar KR, Rachakonda G, Freeman ML. Cysteine-based regulation of the CUL3 adaptor protein Keap1. Toxicol Appl Pharmacol 2010; 244(1): 21-6.
81. Banning A, Brigelius-Flohe R. NF-kappaB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression. Antioxid Redox Signal 2005; 7(7-8): 889-99.
82. Lee JM, Calkins MJ, Chan K, Kan YW, Johnson JA. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J Biol Chem 2003; 278(14): 12029-38.
83. Fu NY, Sukumaran SK, Kerk SY, Yu VC. Baxbeta: a constitutively active human Bax isoform that is under tight regulatory control by the proteasomal degradation mechanism. Mol Cell 2009; 33(1): 15-29.
84. Kraft DC, Deocaris CC, Wadhwa R, Rattan SI. Preincubation with the proteasome inhibitor MG-132 enhances proteasome activity via the Nrf2 transcription factor in aging human skin fibroblasts. Ann N Y Acad Sci 2006; 1067: 420-4.
85. Rajesh A, Sagar R, Singh S, et al. Cytoprotective effect of Podophyllum hexandrum against gamma radiation is mediated via hemopoietic system stimulation and up-regulation of hemeoxygenase-1 and the prosurvival multidomain protein Bcl-2. Integr Cancer Ther 2007; 6(1): 54-65.
86. Cao C, Lu S, Kivlin R, et al. AMP-activated protein kinase contributes to UV-and H2O2-induced apoptosis in human skin keratinocytes. J Biol Chem 2008; 283(43): 28897-908.
87. Achanta P, Thompson KJ, Fuss M, Martinez JL, Jr. Gene expression changes in the rodent hippocampus following whole brain irradiation. Neurosci Lett 2007; 418(2): 143-8.
88. Matsubara J, Tajima Y, Karasawa M. Metallothionein induction as a potent means of radiation protection in mice. Radiat Res 1987; 111(2): 267-75.
89. Matsubara J, Tajima Y, Karasawa M. Promotion of radioresistance by metallothionein induction prior to irradiation. Environ Res 1987; 43(1): 66-74.
90. Ogata H, Izumo Y. [Mortality reduction in mice administered a single abundant dose of zinc, manganese or magnesium after irradiation by gamma-rays at sublethal doses]. Radioisotopes 1990; 39(12): 573-6.
91. Kagimoto O, Naganuma A, Imura N, Toge T, Niwa O, Yokoro K. Effect of the administration of bismuth nitrate on radiogenic thymoma induction in mice. J Radiat Res (Tokyo) 1991; 32(4): 417-28.
92. Koropatnick J, Pearson J. Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein. Mol Pharmacol 1993; 44(1): 44-50.
93. Budagov RS, Ul'ianova LP, Smoryzanova OA, Rott GM. [Increase in the level of metallothioneins in mouse liver after administration of cadmium chloride does not protect from combined radiationthermal injury]. Radiats Biol Radioecol 2001; 41(6): 671-6.
94. Shibuya K, Suzuki JS, Kito H, Naganuma A, Tohyama C, Satoh M. Protective role of metallothionein in bone marrow injury caused by X-irradiation. J Toxicol Sci 2008; 33(4): 479-84.
95. Lorimore SA, Coates PJ, Wright EG. Radiation-induced genomic instability and bystander effects: inter-related nontargeted effects of exposure to ionizing radiation. Oncogene 2003; 22(45): 7058-69.
96. Gurova KV, Hill JE, Guo C, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102(48): 17448-53.
97. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003; 3(2): 117-29.
98. Botchkarev VA, Komarova EA, Siebenhaar F, et al. p53 Involvement in the control of murine hair follicle regression. Am J Pathol 2001; 158(6): 1913-9.
99. Burger A, Loffler H, Bamberg M, Rodemann HP. Molecular and cellular basis of radiation fibrosis. Int J Radiat Biol 1998; 73(4): 401-8.
100. Komarov PG, Komarova EA, Kondratov RV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285(5434): 1733-7.
101. Komarova EA, Kondratov RV, Wang K, et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 2004; 23(19): 3265-71.
102. Mihara M, Erster S, Zaika A, et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11(3): 577-90.
103. Chipuk JE, Green DR. Cytoplasmic p53: bax and forward. Cell Cycle 2004; 3(4): 429-31.
104. Strom E, Sathe S, Komarov PG, et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2(9): 474-9.
105. Qiu W, Carson-Walter EB, Liu H, et al. PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2008; 2(6): 576-83.
106. Wambi C, Sanzari J, Wan XS, et al. Dietary antioxidants protect hematopoietic cells and improve animal survival after total-body irradiation. Radiat Res 2008; 169(4): 384-96.
107. Lee JH, Lee B, Lee HS, et al. Lactobacillus suntoryeus inhibits pro-inflammatory cytokine expression and TLR-4-linked NFkappaB activation in experimental colitis. Int J Colorectal Dis 2009; 24(2): 231-7.
108. Grant GA, Barlow JA, Leach KE. Modification of survival of gamma irradiated mice by adenosine nucleotides. Strahlentherapie 1976; 152(3): 285-91.
109. Kozyreva EV, Eliseenko NN, Iashkin PN, Tikhomirova MV. [ADP as one of the possible regulators of recovery processes in the cell and body following irradiation]. Radiobiologiia 1977; 17(5): 733-8.
110. Langendorff H, Langendorff M. Chemical radiation protection and the c AMP mechanism. Int J Radiat Biol Relat Stud Phys Chem Med 1971; 19(5): 493-5.
111. Tikhomirova MV, Iashkin PN. [Comparative radioprotective activity of adenylates in short-term and prolonged gammairradiation]. Radiobiologiia 1983; 23(1): 100-4.
112. Tikhomirova MV, Rogozkim VD. [Action of ADP in irradiation at a high and low dosage rate]. Radiobiologiia 1979; 19(2): 241-5.
113. Gudkov SV, Gudkova OY, Chernikov AV, Bruskov VI. Protection of mice against X-ray injuries by the post-irradiation administration of guanosine and inosine. Int J Radiat Biol 2009; 85(2): 116-25.
114. Hennig UG, Wang Q, Gee NH, von Borstel RC. Protection and repair of gamma-radiation-induced lesions in mice with DNA or deoxyribonucleoside treatments. Mutat Res 1996; 350(1): 247-54.
115. Hofer M, Pospisil M, Znojil V, et al. Drugs elevating extracellular adenosine promote regeneration of haematopoietic progenitor cells in severely myelosuppressed mice: their comparison and joint effects with the granulocyte colony-stimulating factor. Eur J Haematol 2002; 68(1): 4-11.
116. Hou B, Xu ZW, Yang CW, Gao Y, Zhao SF, Zhang CG. Protective effects of inosine on mice subjected to lethal total-body ionizing irradiation. J Radiat Res (Tokyo) 2007; 48(1): 57-62.
117. Liu WC, Wang SC, Tsai ML, et al. Protection against Radiation-Induced Bone Marrow and Intestinal Injuries by Cordyceps sinensis, a Chinese Herbal Medicine. Radiat Res 2006; 166(6): 900-7.
118. Liu WC, Chuang WL, Tsai ML, Hong JH, McBride WH, Chiang CS. Cordyceps sinensis health supplement enhances recovery from taxol-induced leukopenia. Exp Biol Med (Maywood) 2008; 233(4): 447-55.
119. Zhou X, Luo L, Dressel W, et al. Cordycepin is an immunoregulatory active ingredient of Cordyceps sinensis. Am J Chin Med 2008; 36(5): 967-80.
120. Hofer M, Pospisil M, Znojil V, Hola J, Streitova D, Vacek A. Homeostatic action of adenosine A3 and A1 receptor agonists on proliferation of hematopoietic precursor cells. Exp Biol Med (Maywood) 2008; 233(7): 897-900.
121. Hofer M, Pospisil M, Znojil V, Hola J, Vacek A, Streitova D. Adenosine A(3) receptor agonist acts as a homeostatic regulator of bone marrow hematopoiesis. Biomed Pharmacother 2007; 61(6): 356-9.
122. Hofer M, Vacek A, Pospisil M, Hola J, Streitova D, Znojil V. Activation of adenosine A(3) receptors potentiates stimulatory effects of IL-3, SCF, and GM-CSF on mouse granulocytemacrophage hematopoietic progenitor cells. Physiol Res 2009; 58(2): 247-52.
123. Ohta A, Madasu M, Kini R, Subramanian M, Goel N, Sitkovsky M. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol 2009; 183(9): 5487-93.
124. Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A. Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol 2008; 153 (Suppl 1): S457-64.
125. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxiaadenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008 Oct 1; 14(19): 5947-52.
126. Louis NA, Robinson AM, MacManus CF, Karhausen J, Scully M, Colgan SP. Control of IFN-alphaA by CD73: implications for mucosal inflammation. J Immunol 2008; 180(6): 4246-55.
127. Sag D, Carling D, Stout RD, Suttles J. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol 2008; 181(12): 8633-41.
128. Su Y, Huang X, Raskovalova T, et al. Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 2008; 57(11): 1611-23.
129. Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458(7240): 904-8.
130. Antonioli L, Fornai M, Colucci R, et al. Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications. Pharmacol Ther 2008; 120(3): 233-53.
131. Ohta A, Sitkovsky M. The adenosinergic immunomodulatory drugs. Curr Opin Pharmacol 2009; 9(4): 501-6.
132. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226: 10-8.
133. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006; 442(7098): 39-44.
134. Robinson MJ, Sancho D, Slack EC, LeibundGut-Landmann S, Reise Sousa C. Myeloid C-type lectins in innate immunity. Nat Immunol 2006; 7(12): 1258-65.
135. Feuillet V, Medjane S, Mondor I, et al. Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci USA 2006; 103(33): 12487-92.
136. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 2009; 87(2): 125-38.
137. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13(9): 1050-9.
138. Lotze MT, Zeh HJ, Rubartelli A, et al. The grateful dead: damageassociated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007; 220: 60-81.
139. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006; 311: 1-16.
140. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320(5873): 226-30.
141. Vijay-Kumar M, Aitken JD, Sanders CJ, et al. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J Immunol 2008; 180(12): 8280-5.
142. Neta R. Role of cytokines in radioprotection. Pharmacol Ther 1988; 39(1-3): 261-6.
143. Zucali JR, Suresh A, Tung F, Eastgate J, Nick H, Moreb J. Cytokine protection of hematopoietic stem cells. Prog Clin Biol Res 1994; 389(207): 207-16.
144. Schwartz GN, Patchen ML, Neta R, MacVittie TJ. Radioprotection of mice with interleukin-1: relationship to the number of erythroid and granulocyte-macrophage colony-forming cells. Radiat Res 1990; 121: 220-6.
145. Dubois CM, Neta R, Keller JR, Jacobsen SE, Oppenheim JJ, Ruscetti F. Hematopoietic growth factors and glucocorticoids synergize to mimic the effects of IL-1 on granulocyte differentiation and IL-1 receptor induction on bone marrow cells in vivo. Exp Hematol 1993; 21(2): 303-10.
146. Neta R, Perlstein R, Vogel SN, Ledney GD, Abrams J. Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor. J Exp Med 1992; 175(3): 689-94.
147. Wu SG, Miyamoto T. Radioprotection of the intestinal crypts of mice by recombinant human interleukin-1 alpha. J Immunol 1990; 145(2): 489-98.
148. Johnke RM, Smith ES, Cariveau MJ, et al. Radioprotection of murine gastrointestinal epithelium by interleukin-1alpha involves down-regulation of the apoptotic response. Anticancer Res 2008; 28(6A): 3601-7.
149. Slordal L, Muench MO, Warren DJ, Moore MA. Radioprotection by murine and human tumor-necrosis factor: dose-dependent effects on hematopoiesis in the mouse. Eur J Haematol 1989; 43(5): 428-34.
150. Dalmau SR, Freitas CS, Tabak DG. Interleukin-1 and tumor necrosis factor-alpha as radio-and chemoprotectors of bone marrow. Bone Marrow Transplant 1993; 12(6): 551-63.
151. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T. In vivo and in vitro stem cell function of c-kit-and Sca-1-positive murine hematopoietic cells. Blood 1992; 80(12): 3044-50.
152. Zsebo KM, Smith KA, Hartley CA, et al. Radioprotection of mice by recombinant rat stem cell factor. Proc Natl Acad Sci USA 1992; 89(20): 9464-8.
153. Neta R, Oppenheim JJ, Wang JM, Snapper CM, Moorman MA, Dubois CM. Synergy of IL-1 and stem cell factor in radioprotection of mice is associated with IL-1 up-regulation of mRNA and protein expression for c-kit on bone marrow cells. J Immunol 1994; 153(4): 1536-43.
154. Leigh BR, Khan W, Hancock SL, Knox SJ. Stem cell factor enhances the survival of murine intestinal stem cells after photon irradiation. Radiat Res 1995; 142(1): 12-5.
155. Maddens S, Charruyer A, Plo I, et al. Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect. Blood 2002; 100(4): 1294-301.
156. Perez-Losada J, Sanchez-Martin M, Perez-Caro M, Perez-Mancera PA, Sanchez-Garcia I. The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug. Oncogene 2003; 22(27): 4205-11.
157. Neta R, Douches S, Oppenheim JJ. Interleukin 1 is a radioprotector. J Immunol 1986; 136: 2483-5.
158. Uckun FM, Souza L, Waddick KG, Wick M, Song CW. In vivo radioprotective effects of recombinant human granulocyte colonystimulating factor in lethally irradiated mice. Blood 1990; 75(3): 638-45.
159. Neta R. Radioprotection and therapy of radiation injury with cytokines. Int J Immunopharmacol 1990; 12(5): 491-6.
160. Patchen ML, Fischer R, MacVittie TJ, Seiler FR, Williams DE. Mast cell growth factor (C-kit ligand) in combination with granulocyte-macrophage colony-stimulating factor and interleukin-3: in vivo hemopoietic effects in irradiated mice compared to in vitro effects. Biotherapy 1993; 7(1): 13-26.
161. Neta R, Stiefel SM, Ali N. In lethally irradiated mice interleukin-12 protects bone marrow but sensitizes intestinal tract to damage from ionizing radiation. Ann N Y Acad Sci 1995; 762: 274-80; discussion 80-1.
162. Neta R. Modulation with cytokines of radiation injury: suggested mechanisms of action. Environ Health Perspect 1997; 105 Suppl 6(3): 1463-5.
163. Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA 2005; 102(1): 99-104.
164. McBride WH. Cytokine cascades in late normal tissue radiation responses. Int J Radiat Oncol Biol Phys 1995; 33(1): 233-4.
165. Chiang CS, Sawyers CL, McBride WH. Oncogene Expression and Cellular Radiation Resistance: A Modulatory Role for c-myc. Mol Diagn 1998; 3(1): 21-7.
166. Contessa JN, Hampton J, Lammering G, et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002; 21(25): 4032-41.
167. Dent P, Reardon DB, Park JS, et al. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 1999; 10(8): 2493-506.
168. Zhan M, Han ZC. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 2004; 19(3): 915-23.
169. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiationinduced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15(10): 1191-7.
170. Dent P, Yacoub A, Contessa J, et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003; 159(3): 283-300.
171. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncologica 1988; 27: 131-45.
172. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005; 280(35): 31182-9.
173. Chen CS, Wang YC, Yang HC, et al. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007; 67(11): 5318-27.
174. Dittmann K, Mayer C, Wanner G, Kehlbach R, Rodemann HP. The radioprotector O-phospho-tyrosine stimulates DNA-repair via epidermal growth factor receptor-and DNA-dependent kinase phosphorylation. Radiother Oncol 2007; 84(3): 328-34.
175. Dittmann KH, Mayer C, Ohneseit PA, et al. Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism. Int J Radiat Oncol Biol Phys 2008; 70(1): 203-12.
176. Wanner G, Mayer C, Kehlbach R, Rodemann HP, Dittmann K. Activation of protein kinase Cepsilon stimulates DNA-repair via epidermal growth factor receptor nuclear accumulation. Radiother Oncol 2008; 86(3): 383-90.
177. Ding I, Wu T, Matsubara H, et al. Acidic fibroblast growth factor (FGF1) increases survival and haematopoietic recovery in total body irradiated C3H/HeNCr mice. Cytokine 1997; 9(1): 59-65.
178. Okunieff P, Mester M, Wang J, et al. In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice. Radiat Res 1998; 150(2): 204-11.
179. Okunieff P, Wu T, Huang K, Ding I. Differential radioprotection of three mouse strains by basic or acidic fibroblast growth factor. Br J Cancer Suppl 1996; 27: S105-8.
180. Kolesnick RN, Haimovitz-Friedman A, Fuks Z. The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. Biochem Cell Biol 1994; 72(11-12): 471-4.
181. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293(5528): 293-7.
182. Motomura K, Hagiwara A, Komi-Kuramochi A, et al. An FGF1: FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection. Biochim Biophys Acta 2008; 1780(12): 1432-40.
183. Takahama Y, Ochiya T, Tanooka H, et al. Adenovirus-mediated transfer of HST-1/FGF-4 gene protects mice from lethal irradiation. Oncogene 1999; 18(43): 5943-7.
184. Konishi H, Kuroda S, Tanaka M, et al. Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun 1995; 216(2): 526-34.
185. Maclachlan T, Narayanan B, Gerlach VL, et al. Human fibroblast growth factor 20 (FGF-20; CG53135-05): a novel cytoprotectant with radioprotective potential. Int J Radiat Biol 2005; 81(8): 567-79.
186. Okunieff P, Hammond E, Grignon D, et al. Radiation Therapy Oncology Group. Research Plan 2002-2006. Translational Research Program. Int J Radiat Oncol Biol Phys 2001; 51(3 Suppl 2): 75-87.
187. Ma J, Doig AJ, Patel N, Cui NJ, Terry NH. Modulating effect of keratinocyte growth factor on cellular kinetics of murine lung(I). Ai Zheng 2003; 22(11): 1127-34.
188. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351(25): 2590-8.
189. Brizel DM, Herman TS, Goffinet D, et al. A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer (HNC) patients receiving radiotherapy (RT) with concurrent chemotherapy (CCT) Int J Radiat Oncol Biol Phys 2001; 51(3): 40.
190. Pohlers D, Brenmoehl J, Loffler I, et al. TGF-beta and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 2009; 1792(8): 746-56.
191. Arora PD, McCulloch CA. The deletion of transforming growth factor-beta-induced myofibroblasts depends on growth conditions and actin organization. Am J Pathol 1999; 155(6): 2087-99.
192. Randall K, Coggle JE. Expression of transforming growth factorbeta 1 in mouse skin during the acute phase of radiation damage. Int J Radiat Biol 1995; 68(3): 301-9.
193. Randall K, Coggle JE. Long-term expression of transforming growth factor TGF beta 1 in mouse skin after localized betairradiation. Int J Radiat Biol 1996; 70(3): 351-60.
194. Schultze-Mosgau S, Wehrhan F, Rodel F, et al. Anti-TGFbeta1 antibody for modulation of expression of endogenous transforming growth factor beta 1 to prevent fibrosis after plastic surgery in rats. Br J Oral Maxillofac Surg 2004; 42(2): 112-9.
195. Flanders KC, Ho BM, Arany PR, et al. Absence of Smad3 induces neutrophil migration after cutaneous irradiation: possible contribution to subsequent radioprotection. Am J Pathol 2008; 173(1): 68-76.
196. Flanders KC, Major CD, Arabshahi A, et al. Interference with transforming growth factor-beta/ Smad3 signaling results in accelerated healing of wounds in previously irradiated skin. Am J Pathol 2003; 163(6): 2247-57.
197. Arany PR, Flanders KC, DeGraff W, Cook J, Mitchell JB, Roberts AB. Absence of Smad3 confers radioprotection through modulation of ERK-MAPK in primary dermal fibroblasts. J Dermatol Sci 2007; 48(1): 35-42.
198. Anscher MS, Thrasher B, Rabbani Z, Teicher B, Vujaskovic Z. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int J Radiat Oncol Biol Phys 2006; 65(3): 876-81.
199. Robbins ME, Diz DI. Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 2006; 64(1): 6-12.
200. Cohen EP, Fish BL, Moulder JE. Treatment of radiation nephropathy with captopril. Radiat Res 1992; 132: 346-50.
201. Geraci JP, Sun MC, Mariano MS. Amelioration of radiation nephropathy in rats by postirradiation treatment with dexamethasone and/or captopril. Radiat Res 1995; 143: 58-68.
202. Moulder JE, Cohen EP, Fish BL, Hill P. Prophylaxis of bone marrow transplant nephropathy with captopril, an inhibitor of angiotensin-converting enzyme. Radiat Res 1993; 136(3): 404-7.
203. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors. Int J Radiat Oncol Biol Phys 1993; 27(1): 93-9.
204. Molteni A, Moulder JE, Cohen EP, et al. Prevention of radiationinduced nephropathy and fibrosis in a model of bone marrow transplant by an angiotensin II receptor blocker. Exp Biol Med (Maywood) 2001; 226(11): 1016-23.
205. Moulder JE, Robbins ME, Cohen EP, Hopewell JW, Ward WF. Pharmacologic modification of radiation-induced late normal tissue injury. Cancer Treat Res 1998; 93: 129-51.
206. Moulder JE, Fish BL, Cohen EP. Treatment of radiation nephropathy with ACE inhibitors and AII type-1 and type-2 receptor antagonists. Curr Pharm Des 2007; 13(13): 1317-25.
207. Coleman CN, Stone HB, Moulder JE, Pellmar TC. Medicine. Modulation of radiation injury. Science 2004; 304(5671): 693-4.
208. Stone HB, Moulder JE, Coleman CN, et al. Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res 2004; 162(6): 711-28.
209. Moulder JE, Fish BL, Cohen EP. ACE Inhibitors and AII Receptor Antagonists in the Treatment and Prevention of Bone Marrow Transplant Nephropathy. Curr Pharm Des 2003; 9(9): 737-49.
210. Moulder JE, Fish BL, Cohen EP, Bonsib SM. Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiat Res 1996; 146(1): 106-10.
211. Moulder JE, Cohen EP. Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol 2007; 17(2): 141-8.
212. Ward WF, Lin PJ, Wong PS, Behnia R, Jalali N. Radiation pneumonitis in rats and its modification by the angiotensinconverting enzyme inhibitor captopril evaluated by high-resolution computed tomography. Radiat Res 1993; 135(1): 81-7.
213. Ward WF, Molteni A, Ts'ao CH, Hinz JM. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys 1990; 19(6): 1405-9.
214. Molteni A, Moulder JE, Cohen EF, et al. Control of radiationinduced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000; 76(4): 523-32.
215. Ward WF, Molteni A, Ts'ao CH, Kim YT, Hinz JM. Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 1992; 22(3): 623-5.
216. Kim JH, Brown SL, Kolozsvary A, et al. Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat. Radiat Res 2004; 161(2): 137-42.
217. Robbins ME, Payne V, Tommasi E, et al. The AT1 receptor antagonist, L-158, 809, prevents or ameliorates fractionated wholebrain irradiation-induced cognitive impairment. Int J Radiat Oncol Biol Phys 2009; 73(2): 499-505.
218. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem 2009; 16(2): 130-43.
219. Border WA, Noble NA. Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998; 31(1 Pt 2): 181-8.
220. Peters H, Border WA, Noble NA. Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998; 54(5): 1570-80.
221. Gomez-Garre D, Ruiz-Ortega M, Ortego M, et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996; 27(4): 885-92.
222. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997; 51(3): 664-71.
223. Hanna IR, Taniyama Y, Szocs K, Rocic P, Griendling KK. NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal 2002; 4(6): 899-914.
224. Komazaki T, Nagai H, Emi M, et al. Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 2004; 34(4): 191-4.
225. Xiao F, Puddefoot JR, Barker S, Vinson GP. Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 2004; 44(3): 340-5.